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Endoscopic Molecular Imaging: Status and Future Perspective
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During the last decade, researchers have made great progress in the development of new image processing technologies for gastrointesti-
nal endoscopy. However, diagnosis using conventional endoscopy with white light optical imaging is essentially limited, and ultimately, 
we still rely on the histopathological diagnosis from biopsy specimens. Molecular imaging represents the most novel imaging methods 
in medicine, and the future of endoscopic diagnosis is likely to be impacted by a combination of biomarkers and technology. Endoscopic 
molecular imaging can be defined as the visualization of molecular characteristics with endoscopy. These innovations will allow us not 
only to locate a tumor or dysplastic lesion but also to visualize its molecular characteristics and the activity of specific molecules and bio-
logical processes that affect tumor behavior and/or its response to therapy. In the near future, these promising technologies will play a 
central role in endoluminal oncology. 
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INTRODUCTION
Gastrointestinal endoscopy has been widely used for detec-
tion, differentiation, and staging of neoplasia in the digestive 
tract and has made great progress during the last decade.1 Di-
agnostic accuracy can be enhanced by better training, more 
efficient techniques, and the development of new image-pro-
cessing technologies;2 however, diagnosis using conventional 
endoscopy with optical characteristics is essentially limited 
because it is based on morphological changes and/or discol-
oration. Chromoendoscopy can enhance surface structure and 
is used to determine demarcation borders; however, it is not 
sensitive enough to detect early-stage cancer because the di-
agnosis still depends on the endoscopist’s expertise and biop-
sy. Autofluorescence imaging has been used for lesions that 
are difficult to identify morphologically or are indistinguish-
able by white light endoscopy, and this technique is potential-
ly applicable for the diagnosis of dysplastic lesions and early-
stage cancers in the gastrointestinal tract.3 Optical digital 
enhancing methods such as narrow band imaging,4 flexible 
spectral imaging color enhancement,5 and i-SCAN6 are novel 
endoscopic techniques that can distinguish neoplastic and 
nonneoplastic lesions without a dye. Magnifying endoscopy 
in combination with an optical digital method has an obvious 
advantage in that it allows analysis of the epithelial pit pattern 
and the vascular network. Other techniques allow visualiza-
tion of cell morphology on the micro-level, thus reflecting mi-
croscopic characteristics.7 Given the differing statuses of vari-
ous optical imaging modalities, in 2008, Tajiri and Niwa8 
proposed a consensus on how different endoscopic imaging 
techniques should be grouped and defined. They divided en-
doscopic imaging methods into five categories: conventional 
endoscopy, image-enhanced endoscopy, magnified endosco-
py, endoscopic microscopy, and tomographic imaging (Fig. 1). 
Based on this classification, we are encouraged to resolve is-
sues such as how to combine these techniques in diagnostic 
strategies, how to apply them in algorithms for therapeutic de-
cisions, and how to standardize several morphological classi-
fications utilized in these techniques, especially in the field of 
endoluminal oncology (Fig. 2).
Molecular imaging represents the most novel imaging meth-
ods in medicine, and the definition of the term is still not es-
tablished. It is broadly defined as the in vivo characterization 
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and measurement of a biological process at the cellular molec-
ular level9 or a technique that directly or indirectly monitors 
and records the spatiotemporal distribution of molecular and 
cellular processes for biochemical, biological, diagnostic, or 
therapeutic application.10 Positron emission tomography (PET) 
might be included in a wide concept of molecular imaging 
methods: the detection, spatial localization, and quantifica-
tion of specific molecular targets and events that form the 
basis of pathologies.11 In the clinical setting of different medi-
cal specializations, a major paradigm shift has been rapidly 
taking place in imaging technology represented by PET. The 
future of endoscopic diagnosis is likely to be affected by a 
combination of biomarkers and technology,12 and endoscop-
ic molecular imaging can be defined as visualization of mo-
lecular characteristics; it has been described as immunosco-
py,13 bioendoscopy,14 and optical biopsy.15 Before endoscopic 
molecular imaging can be realized, three prerequisites must 
be available: 1) more target-specific and highly sensitive bio-
markers for clinical use; 2) fluorochromes that have a high af-
finity for the markers and can produce a distinct signal; and 3) 
equipment to visualize the indicator at high resolution in real 
time. These innovations will allow identification of tumor lo-
cation. In addition, they will be useful to: 1) differentiate ma-
lignant and benign polyps and ulcers; 2) minimize the number 
of biopsies and frequency of surveillance; 3) provide accurate 
preoperative identification of tumor margins; 4) evaluate the 
effectiveness of pharmacological therapy; and 5) detect local 
dysplasia in inflamed mucosa such as Barrett esophagus or 
ulcerative colitis. These new developments will also allow us 
to visualize a tumor’s molecular characteristics and monitor 
the activity of specific molecules and biological processes that 
affect tumor behavior and/or its response to therapy.16,17 Ad-
ditionally, endoscopic molecular imaging could greatly im-
pact personalized medicine for treating cancer with the de-
velopment of molecular targeting therapies.18 In this paper, 
we describe the advancement of this new technology and 
preview future perspectives in the developing molecular era 
in gastrointestinal endoscopy.
TARGET BIOMARKERS
Gastrointestinal cancer arises in every segment of the di-
gestive tract: the esophagus, stomach, duodenum, small intes-
tine, and colon. A large mucosal area has the potential for de-
veloping neoplastic lesions. However, the most common sites 
associated with cancer mortality reflect the role of particular 
organs as targets for the development of endoscopic molecu-
lar imaging. Thus, reports from Europe and the United States 
are focused on colorectal carcinoma and dysplasia in Barrett 
esophagus,19-21 whereas those from Japan focus on gastric can-
cer.22 Essentially, the causes of cancer vary by organ, and can-
cer is affected by many factors during its development.23 In 
terms of biomarkers, there are two different methods to detect 
a neoplasia: using epigenetic markers on tissues during cancer 
development or utilizing ligands produced by the developed 
cancer. Several kinds of molecules or epitopes can be targeted, 
such as those involved in genetic mutations in the APC, K-
RAS, and p53 genes, microsatellite instability,20,24 and apopto-
sis.25 Endostatin and proteases such as cathepsin B are upreg-
ulated in areas of focal invasion of colorectal carcinomas and 
in dysplastic adenomas.20,24,26 Epidermal growth factor recep-























Fig. 1. Endoscopic imaging classification proposed by Tajiri and 
Niwa (modified by the authors). FICE, flexible spectral imaging col-
or enhancement; NBI, narrow band imaging; AFI, autofluorescence 
imaging.
Fig. 2. Strategy based on the imaging classification in endoluminal 
oncology. ESD, endoscopic submucosal dissection; EMR, endo-
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and carcinoembryonic antigen (CEA),22 which are highly ex-
pressed in digestive tract cancers, are also important candi-
dates. Mucin, a glycoprotein containing a large amount of sug-
ar, is the main component of mucus, and the peptide structure 
of the mucin core protein has been determined. The specific 
expression of mucin in various digestive tract cancers has been 
studied.30 Based on the ability to measure it with a relatively 
high sensitivity, mucin is a useful biomarker that should be 
targeted. Currently, therapeutic antibodies are exploited and 
used in various diseases, including colorectal cancer, and this 
is particularly true for molecular imaging applications, in 
which imaging and therapeutic targeting are often the same.31
MOLECULAR PROBES
Principally, molecular probes are administered in an exog-
enous fashion and usually target a disease-specific biomarker. 
The best molecular probes are highly specific with a high tis-
sue/background ratio and a high binding affinity to the tar-
gets. Such probes include antibodies, antibody fragments, 
peptides, nanoparticles, and activatable probes. Characteris-
tic advantages and disadvantages exist among them (Fig. 3).32 
The two most common classes of molecular probes being 
developed for clinical use include antibodies and peptides. 
Antibodies are Y-shaped γ globulins (immunoglobulin G) 
that are highly specific for known targets and have been trans-
lated into the clinical setting recently. They can be labeled with 
a variety of fluorescent dyes and have been developed for sev-
eral molecular targets in EGFR, VEGF, CEA, and mucin. As 
diagnostic markers in molecular imaging, monoclonal anti-
bodies have been and still are promising and efficient, but the 
sensitivity and specificity of immunofluorescence depend on 
those properties of native monoclonal antibodies. Converse-
ly, antibodies may confer allergic reactions after systemic ap-
plication, and their diffusion across epithelial borders and 
delivery to target structures are slow owing to their molecular 
weight.32 Peptides are short chains of amino acids that can be 
labeled with fluorescent dyes relatively easily and have been 
successfully selected using phage display techniques. Peptides 
are considered to have a high affinity for a specific partner 
and they should internalize, not remain cell-surface bound, to 
maximize cellular trapping and increase local concentration.33 
Activatable probes are designed to generate fluorescence only 
after coming into contact with the target. These probes are 
fluorescently quenched in their native state and activated 
when they are cleaved by or react with tumor-associated en-
zymes, which play an important role in tumor proliferation, 
invasion, apoptosis, and metastasis.20,34
OPTICAL CONTRAST AGENTS
Components or elements of the living body emit fluores-
cence at 310 to 540 nm when excited at 280 to 370 nm. Infra-
red light has wavelengths between 700 and 1,000 nm that 
show higher permeation and safety than ultraviolet rays. Ad-
ditionally, there is little background noise in the body, espe-
cially in the digestive tract, when infrared light is applied. 
Agents that are excitable by infrared light seem to be suitable 
for immunofluorescence. Near-infrared light includes wave-
lengths between 700 and 1,000 nm, and near-infrared fluo-
rescence is widely applied for in vivo molecular imaging be-
cause of greater tissue penetration, less autofluorescence 
background, and reduced hemoglobin absorption.24,26,35 The 
Alexa Fluor dye family is produced by the company, Molecu-
Fig. 3. Comparison of different molecular probe classes. Adapted from Goetz et al. Gastroenterology 2010;138:828-833, with permission 
from Elsevier.32 ab, antibody.
Type Peptide Antibody Activatible probe Nanoparticle






·  Defined and approved 
  therapeutic ab may be 
  labeled
· Specific activation
·  Optimized signal-to- 
  noise ratio
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  targeting
· Strong fluorescence
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lar Probes (Invitrogen, Carlsbad, CA, USA). These materials 
are synthesized through sulfonation of coumarin, rhodamine, 
xanthene, and cyanine dyes, and are often used as cell and tis-
sue labels in fluorescence microscopy and cell biology. Alexa 
Fluor dyes are generally more stable and brighter than com-
mon dyes. The emission spectrum of the materials ranges 
from 442 to 810 nm. The IRDye family from LI-COR, HiLyte 
Fluor dyes from AnaSpec, and DyLight Fluor dyes produced 
by Dyomics in collaboration with Thermo Fisher Scientific 
(Hudson, NH, USA) are similar to Alexa Fluor dyes in spec-
trum characteristics and can be used alternatively. However, 
the toxicity of each material used for laboratory investigation 
should be considered before it is approved for clinical use. A 
strong affinity for the antibodies or peptides and intense fluo-
rescence are also required for optimal probes. Quantum dots 
(QDs) are semiconductor nanocrystals that contain an inor-
ganic core of metal and an outer soluble organic coating. They 
are highly fluorescent in the near-infrared region, nonradio-
active, and easily visible deep within the tissues. In the clinic, 
they are applied for sentinel lymph node mapping and cancer 
imaging.36 However, the potential toxicity of QD is a limita-
tion to their clinical use because they contain heavy metals at 
their core with an amphiphilic organic coating. Cadmium, tel-
luride, selenide, and alkyl phosphines cause acute and chronic 
toxic disorders, although their toxicity as precomplexed nano-
crystals is unknown.
Indocyanine green (ICG) is also a water-soluble fluores-
cent agent that emits light at 807 to 832 nm upon excitation 
around 770 nm.37 ICG is a clinically available compound that 
seems suitable as a molecular imaging agent;38 however, in the 
clinical use of these labeling agents, the toxicity of each la-
beled material should be evaluated before it is approved for 
clinical use. Moreover, several problems such as the affinity to 
antibodies, stability in the body, and intensity of fluorescent 
signal, should be solved before clinical use.
ADMINISTRATION OF CONTRAST 
PROBES
To utilize immunofluorescence in endoscopic diagnostics, 
it is essential that the probe shows in vivo immunofluores-
cence. This method uses exogenous diagnostic markers in a 
technique that is essentially different from newly developed 
autofluorescence imaging, which is based on endogenous flu-
orescence of materials such as collagen. The best way to ad-
minister the probe, by injection or topically, to a patient is con-
troversial even now. Administration by injection is anticipated 
to reduce the affinity and decrease the fluorescence intensity 
of the markers during circulation because evoking the adverse 
effects of the markers demands large amounts of the antibody 
Fig. 4. In vivo confocal fluorescence images of the border between a colonic adenoma and normal mucosa showing peptide binding to dys-
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Fig. 5. Molecular imaging of an esophagectomy specimen with a 6-cm segment of Barrett esophagus containing macroscopically invisible resid-
ual high grade dysplasia (HGD) and focal intramucosal carcinoma. (A) Images taken with an endoscope. White-light image (left), imaging fluo-
rescence at 490 to 560 nm before white germ agglutinin. Application (middle) and imaging fluorescence at 490 to 560 nm after wheat germ ag-
glutinin (WGA) and Alexa Fluor 488 application (right). The areas of low WGA binding appear in purple. (B) The dashed white line is placed 
longitudinally along the posterior wall of the esophagus to facilitate orientation between the different images, and the numbers 7, 8, and 9 refer to 
the y coordinates on the reference grid in. White-light imaging of the lower esophagus revealed no macroscopic abnormalities such as ulcers or 
nodules, and before WGA application, we detected no appreciable differences in mucosal autofluorescence; however, after incubation with WGA, 
differences in lectin binding were evident. High binding is represented by a green signal and low binding is represented by a purple signal on the 
pseudocolor image. Grid showing the pathological diagnostic map (color-coded, with darker colors representing a worsening grade of dyspla-
sia) of each block made from the resection specimen. This same grid can be compared with the endoscopic and in vivo imaging system (IVIS) 
fluorescence images in (A), on the right, and in (D). The dashed line represents the longitudinal axis along the posterior wall of the esophagus. 
(C) The same specimen after being opened longitudinally along the anterior border of the esophagus is shown with the overlying grid from (B). 
(D) The WGA fluorescence signal from the esophageal specimen taken with the IVIS 200 camera. The pink arrow marks an area of artifact from 
the exposed submucosal tissue, and the blue arrow indicates the site of a previous endoscopic mucosal resection (outlined with a dashed gray 
box). The specimen was cut into 11 transverse sections (rows labeled 1 to 11), and the pathologist divided each of these further into 8 areas (col-
umns labeled A-H) to allow mapping. (E) Examples of the histological appearance (×40) at various coordinates from the grid. From left to right, the 
images show nondysplastic Barrett esophagus, low grade dysplasia (LGD), and two examples of HGD. The corresponding grid reference is giv-
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and the host-immune response to them quickly eliminates the 
antibody and forms immune complexes that damage the kid-
neys.39 For topical administration, tumor exposure is neces-
sary for the reaction, and pretreatment of the gastrointestinal 
mucosa is necessary. In addition, it is necessary to develop an 
endoscope that has a diameter small enough for examination 
and flexibility as an instrument to allow normal observation 
at high definition and rapid switching to molecular imaging 
in real time. However, advances in technology will soon solve 
these problems.
RECENT PROGRESS AND FUTURE 
PERSPECTIVE
Molecular imaging was listed among the 10 emerging tech-
nologies that will change the world by the Massachusetts In-
stitute of Technology 2003 Technology Review. Recently, in 
the United States, the National Institutes of Health launched 
common funding programs including molecular libraries and 
imaging. In the European Union, Diagnostic Molecular Im-
aging (DiMI) and European Master in Molecular Imaging 
(EMMI) programs were established. The DiMI Network of 
Excellence was one of the largest European research projects 
funded by the European Commission within the 6th Frame-
work Programme. EMMI is an international program entirely 
dedicated to in vivo molecular imaging. Supported by the Eu-
ropean Commission under the SOCRATES program, this 
2-year interdisciplinary curriculum is formed by prominent 
European molecular imaging research groups. In response to 
these activities, the new World Molecular Imaging Society 
(WMIS), the world’s most advanced molecular imaging or-
ganization, was formed from a merger of the Society for Mo-
lecular Imaging and the Academy of Molecular Imaging in 
North America. The World Molecular Imaging Congress is 
organized by the joint efforts of the WMIS, the European So-
ciety for Molecular Imaging, and the Federation of Asian So-
cieties for Molecular Imaging. Given this situation, it is very 
likely that molecular imaging is one of the latest upcoming 
and nationwide fields that will affect human life science.
In general, the incidence of colorectal cancer has been in-
creasing worldwide and will occur more frequently in the fu-
ture; therefore, a new technology that is cost-effective and ef-
ficient in both screening and further examinations is required. 
Molecular imaging can add various types of information to 
conventional imaging techniques and can enable not only 
detection and localization but also quantification and deter-
mination of the pathological characteristics.11 Hsiung et al.21 
detected in vivo human colonic dysplasia using a targeted 
heptapeptide and showed impressive images of a dysplastic 
polyp and the border between the normal mucosa and the 
lesion (Fig. 4). Based on their study showing specific changes 
in lectin binding patterns in the progression from Barrett 
esophagus to adenocarcinoma, Bird-Lieberman et al.40 re-
cently succeeded in visualizing high-grade dysplastic lesions 
in Barrett esophagus that were not detectable by convention-
al endoscopy (Fig. 5). Recent concerns and analyses are shift-
ing from in vitro to in vivo studies, from animals to humans, 
and from diagnostic issues to more therapeutically relevant 
subjects. Theragnostics (or theranostics), a term denoting the 
fusion of therapeutics and diagnostics, is receiving increasing 
attention as a key part of personalized medicine.41 Multidis-
ciplinary approaches and collaborative research efforts by 
pharmaceutical scientists and medical doctors will lead to the 
discovery of clinically significant imaging and therapeutic 
agents that may help detect, differentiate, prevent, and cure 
cancer.
In clinical settings, amplification or reinforcement strategies 
are also required, because focal target concentrations are pre-
Fig. 6. Imaging applications in the drug discovery and development process. Adapted from Rudin et al. Nat Rev Drug Discov 2003;2:123-
131, with permission from Nature Publishing Group.31
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sumed quite low, in the picomolar to nanomolar range.42 An 
ideal system in this technology would be a less invasive mo-
dality that offers a strong signal to noise ratio, quantitative 
analysis, real-time monitoring, and multiplex imaging using 
various fluorescent peptides or antibodies with different opti-
cal characteristics.43 There are many alternate molecular path-
ways in carcinoma development; stepwise formation may be 
visualized with various molecules. Before the clinical applica-
tion of molecular agents, pharmacokinetics and pharmacody-
namics should be tested, and these agents must undergo 
lengthy approval processes (Fig. 6);31 however, no definite bar-
riers are anticipated to prevent their eventual clinical applica-
tion because therapeutic administration of various humanized 
antibodies has been proven safe. Conversely, fluorochromes 
such as ICG are photostable and have been used safely in the 
human body. With these possibilities, it seems apparent that 
this innovative technology will be realized in cooperation 
with the pharmaceutical industry and chemical and engineer-
ing companies, and we hope that the industry will economi-
cally invest in endoluminal oncology.
CONCLUSIONS
Endoscopic molecular imaging can be used for cancer 
screening and surveillance and can also provide important 
information for deciding treatment strategies and evaluating 
effectiveness. This technology will paly a central role in en-
doluminal oncology in the near future.
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